U.S. markets close in 5 hours 47 minutes

BioCryst Pharmaceuticals, Inc. (BCRX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
5.47-0.22 (-3.95%)
As of 10:13AM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Slow Stochastic

Slow Stochastic

Previous Close5.69
Bid5.53 x 800
Ask5.54 x 800
Day's Range5.40 - 5.85
52 Week Range4.83 - 12.08
Avg. Volume3,408,355
Market Cap1.12B
Beta (5Y Monthly)1.87
PE Ratio (TTM)N/A
EPS (TTM)-1.25
Earnings DateFeb 19, 2024 - Feb 23, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est14.09
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for BCRX

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • BioCryst Pharmaceuticals, Inc.
    Daily – Vickers Top Buyers & Sellers for 11/26/2021The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Fair Value
    Economic Moat
    2 years agoArgus Research
View more
  • GlobeNewswire

    BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    RESEARCH TRIANGLE PARK, N.C., Dec. 05, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted 16 newly-hired employees stock options to purchase an aggregate of 74,500 shares, and restricted stock units (RSUs) covering an aggregate of 51,050 shares, of BioCryst common stock. The options and RSUs were granted as of November 30, 2023, as inducements material to each employee entering into emplo

  • TipRanks

    J.P. Morgan Recommends These 2 ‘Strong Buy’ Stocks With Over 60% Upside Potential

    November has a been a good month for the markets, with solid gains on the S&P 500 of 8.5%, bringing the year-to-date haul to ~19%. The question now is, where do we go from here? Don’t go anywhere, rather, stay in the stock market, appears to be the recommendation of JPMorgan’s global investment strategist Madison Faller, who points to three factors that should be supportive going forward. First, the US economy is cooling a bit, enough to ease the threat of overheating; second, the rate of inflat

  • GlobeNewswire

    BioCryst Announces Approval of ORLADEYO® (berotralstat) by the National Administration of Drugs, Foods, and Medical Devices (ANMAT) in Argentina

    RESEARCH TRIANGLE PARK, N.C., Nov. 29, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the National Administration of Drugs, Foods, and Medical Devices (ANMAT) in Argentina has granted approval for oral, once-daily ORLADEYO® (berotralstat) for the prophylaxis of hereditary angioedema (HAE) attacks in adults and pediatric patients 12 years of age or older. “We continue to make strides to bring ORLADEYO to patients living with HAE in Latin America in col